Trial Profile
Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease (COPD) During Therapy With Spiolto Respimat [ELLACTO]
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Apr 2020
Price :
$35
*
At a glance
- Drugs Olodaterol/tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms ELLACTO
- Sponsors Boehringer Ingelheim
- 10 Apr 2019 Status changed from active, no longer recruiting to completed.
- 04 Mar 2019 Planned End Date changed from 22 Feb 2019 to 8 Mar 2019.
- 04 Jan 2019 Planned End Date changed from 31 Dec 2018 to 22 Feb 2019.